Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also include antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PAHC
CUSIPN/A
Phone201-329-7300
Debt
Debt-to-Equity Ratio1.62
Current Ratio2.90
Quick Ratio1.66
Price-To-Earnings
Trailing P/E Ratio24.87
Forward P/E Ratio24.31
P/E Growth2.53
Sales & Book Value
Annual Sales$820 million
Price / Sales2.15
Cash Flow$2.4333 per share
Price / Cash17.98
Book Value$4.58 per share
Price / Book9.55
Profitability
EPS (Most Recent Fiscal Year)$1.74
Net Income$64.88 million
Net Margins7.90%
Return on Equity39.81%
Return on Assets10.53%
Miscellaneous
Employees1,500
Outstanding Shares40,370,000
Market Cap$1.77 billion
Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions
What is Phibro Animal Health's stock symbol?
Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."
How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?
Phibro Animal Health announced a quarterly dividend on Monday, July 30th. Shareholders of record on Wednesday, September 5th will be paid a dividend of $0.10 per share on Wednesday, September 26th. This represents a $0.40 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Tuesday, September 4th. View Phibro Animal Health's Dividend History.
How were Phibro Animal Health's earnings last quarter?
Phibro Animal Health Corp (NASDAQ:PAHC) issued its earnings results on Monday, August, 27th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. The company earned $211.80 million during the quarter, compared to analyst estimates of $209.27 million. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.39 earnings per share. View Phibro Animal Health's Earnings History.
When is Phibro Animal Health's next earnings date?
What guidance has Phibro Animal Health issued on next quarter's earnings?
Phibro Animal Health updated its FY19 earnings guidance on Monday, August, 27th. The company provided EPS guidance of $1.72-1.77 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.85. The company issued revenue guidance of $850-875 million, compared to the consensus revenue estimate of $851.06 million.
What price target have analysts set for PAHC?
4 equities research analysts have issued 1 year price objectives for Phibro Animal Health's shares. Their forecasts range from $33.00 to $46.00. On average, they anticipate Phibro Animal Health's stock price to reach $40.75 in the next twelve months. This suggests that the stock has a possible downside of 6.5%. View Analyst Price Targets for Phibro Animal Health.
What is the consensus analysts' recommendation for Phibro Animal Health?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.
Who are some of Phibro Animal Health's key competitors?
Some companies that are related to Phibro Animal Health include Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH) and Taro Pharmaceutical Industries (TARO).
Who are Phibro Animal Health's key executives?
Phibro Animal Health's management team includes the folowing people:
- Mr. Jack Clifford Bendheim, Chairman, Pres & CEO (Age 71)
- Mr. Larry L. Miller, Chief Operating Officer (Age 54)
- Mr. Dean J. Warras, Pres of Animal Health & Nutrition - North America (Age 49)
- Mr. Richard G. Johnson, Chief Financial Officer (Age 69)
- Mr. Thomas G. Dagger, Sr. VP, Gen. Counsel & Corp. Sec. (Age 60)
Has Phibro Animal Health been receiving favorable news coverage?
Media headlines about PAHC stock have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Phibro Animal Health earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Phibro Animal Health.
Who are Phibro Animal Health's major shareholders?
Phibro Animal Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.19%), Renaissance Technologies LLC (1.57%), Dimensional Fund Advisors LP (1.25%), Copper Rock Capital Partners LLC (1.20%), Segall Bryant & Hamill LLC (1.17%) and Northern Trust Corp (1.01%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel A Welch, Daniel M Bendheim, Dean J Warras, Gerald K Carlson, Jack Bendheim, Larry Lee Miller, Richard G Johnson and Thomas G Dagger. View Institutional Ownership Trends for Phibro Animal Health.
Which institutional investors are selling Phibro Animal Health stock?
PAHC stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Millennium Management LLC, American Century Companies Inc., Eagle Asset Management Inc., Sit Investment Associates Inc., Mackay Shields LLC, Russell Investments Group Ltd. and Voya Investment Management LLC. Company insiders that have sold Phibro Animal Health company stock in the last year include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, Jack Bendheim and Larry Lee Miller. View Insider Buying and Selling for Phibro Animal Health.
Which institutional investors are buying Phibro Animal Health stock?
PAHC stock was bought by a variety of institutional investors in the last quarter, including Segall Bryant & Hamill LLC, BlackRock Inc., Renaissance Technologies LLC, Granite Investment Partners LLC, Northern Trust Corp, Fuller & Thaler Asset Management Inc., GSA Capital Partners LLP and Algert Global LLC. View Insider Buying and Selling for Phibro Animal Health.
How do I buy shares of Phibro Animal Health?
Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Phibro Animal Health's stock price today?
One share of PAHC stock can currently be purchased for approximately $43.60.
How big of a company is Phibro Animal Health?
Phibro Animal Health has a market capitalization of $1.77 billion and generates $820 million in revenue each year. The company earns $64.88 million in net income (profit) each year or $1.74 on an earnings per share basis. Phibro Animal Health employs 1,500 workers across the globe.
How can I contact Phibro Animal Health?
Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]
MarketBeat Community Rating for Phibro Animal Health (NASDAQ PAHC)
MarketBeat's community ratings are surveys of what our community members think about Phibro Animal Health and other stocks. Vote "Outperform" if you believe PAHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
